"ESMO 2025: AstraZeneca and Daiichi Sankyo establish Enhertu in early breast cancer" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a ...

The latest investment brings the British pharma’s total investment at the site in Qingdao to $886 million. AstraZeneca ...

(Alliance News) - Daiichi Sankyo Co Ltd and AstraZeneca PLC on Friday said they began new phase 3 clinical trial testing of an intravenous treatment for advanced lung cancer.

Precision oncology is tailoring treatments based on molecular profiles, while new surgical and radiotherapy methods boost recovery. Despite challenges like late diagnosis and high treatment costs, ...

Researchers surveyed 385 women younger than 40 years with advanced breast cancer to gather insights about the challenges ...

Opportunities in the lung cancer antibody drug conjugates market include developing specific, low-toxicity therapies using ADCs, capitalizing on technology platforms like DXd, leveraging collaboration ...

The decision by the Canadian regulator is supported by the findings from the Phase III DESTINY-Breast06 study.

Daiichi Sankyo (TSE:4568) posted 11.8% earnings growth over the last twelve months, trailing its 32.7% average from the past five years. Net profit margin edged down to 14.1% from 14.2% a year ago.

The first patient has been dosed in the DESTINY-Lung06 phase 3 trial evaluating Enhertu plus pembrolizumab versus pembrolizumab, platinum-based ...

The multicentre, randomised trial was conducted in China, but Sichuan-Kelun and Merck & Co will commercialise sac-TMT in other markets.

Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic NSCLC ...